Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma (acute asthma)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Richard Lockey, University of South Florida
ClinicalTrials.gov Identifier:
NCT01690793
First received: August 5, 2010
Last updated: September 18, 2012
Last verified: September 2012

August 5, 2010
September 18, 2012
February 2009
December 2010   (final data collection date for primary outcome measure)
The measurement of NHPs after treatment of an exacerbation of asthma [ Time Frame: 14 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01690793 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma
Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma

The investigators hypothesize that there is a statistically significant decrease of Natriuretic Hormone Peptides (NHPs) in subjects with asthma exacerbation compared to levels following treatment of an exacerbation of asthma.

Overall Study Design

  1. Measurement of Natriuretic Hormone Peptides in individuals suffering from exacerbation of asthma.
  2. Measurement of Natriuretic Hormone Peptides 5-7 days after initiation of treatment of exacerbation of asthma.
  3. Measurement of Natriuretic Hormone Peptides 10-14 days after initiation of treatment of exacerbation of asthma.

3 comparisons of Natriuretic Hormone Peptides levels will be made:

  1. Exacerbation compared to 5-7 days after initiation of treatment
  2. Exacerbation compared to 10-14 days after initiation of treatment
  3. 5-7 days after initiation of treatment compared to 10-14 days after initiation of treatment.

Samples of blood will be secured in the Division of Allergy/Immunology at the University of South Florida, Joy McCann Culverhouse Airways Disease Center. All samples will be appropriately coded to maintain confidentiality. Blood specimens will be held at minus 20 degrees Celsius.

Observational
Not Provided
Not Provided
Retention:   Samples With DNA
Description:

Samples of blood will be secured in the Division of Allergy/Immunology at the University of South Florida, Joy McCann Culverhouse Airways Disease Center. All samples will be appropriately coded to maintain confidentiality. Blood specimens will be held at minus 20 degrees Celsius. GENETICS SAMPLES ARE OPTIONAL

Probability Sample

The Asthma Control Test score of less than 18.

Asthma control test consists of five questions, scored 1-5 each.

ASTHMA
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
February 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Both genders, age 18-85.
  • Females who are pregnant or lactating are not eligible.
  • Read and comprehend English.
  • Ability to give informed consent.
  • Seen in the outpatient setting at one of the clinic.
  • The subject must have a history of physician diagnosed asthma for at least 1 year and must have an exacerbation of asthma for entry into the study.
Both
18 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01690793
acute asthma
No
Richard Lockey, University of South Florida
University of South Florida
Not Provided
Not Provided
University of South Florida
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP